A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

NCT03843125 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1147

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]